Trial Profile
Efficacy and safety of olmesartan: reduction of blood pressure in the treatment of patients suffering from mild to moderate essential hypertension
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 30 Oct 2005
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil (Primary) ; Olmesartan medoxomil/hydrochlorothiazide (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- 30 Oct 2005 New trial record.